Literature DB >> 7802339

[Plasma concentration of C-reactive protein in patients with high estrogen levels].

R Ricoux1, M Pontet, J P Tresca, R Engler.   

Abstract

The monitoring of inflammatory activity in patients with a high level of estrogen is controversial because the significance of a raised estradiol level on C-reactive protein (CRP) concentrations is a debated question. This prompted us to assay CRP by a sensitive Elisa in a sample of 30 patients with ovarian stimulation for in vitro fertilization, thus with high levels of estradiol. For 15 of these women, six to nine plasma samples were analyzed allowing a kinetic study of plasma levels of CRP, estradiol and sex steroid-binding plasma protein (SBP). No significant correlation was found between the concentrations of estradiol and CRP for the 30 patients. In the kinetic study, as mean estradiol levels rose exponentially from 50 to 1400 ng/l between day 5 and 14, the CRP level tended to vary markedly from one patient to another and sometimes from day to day, but there was never any relation with estradiol level. Furthermore, CRP did not significantly modify the slope of the regression line between estradiol concentration and the day of the menstrual cycle. In contrast, the effect of estradiol on SBP was clear, which supports the absence of estradiol effect on CRP level.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7802339

Source DB:  PubMed          Journal:  Ann Biol Clin (Paris)        ISSN: 0003-3898            Impact factor:   0.459


  2 in total

1.  Association of endogenous hormones with C-reactive protein, fibrinogen, and white blood count in post-menopausal women.

Authors:  Aaron R Folsom; Sherita Hill Golden; Lori L Boland; Moyses Szklo
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

2.  Circulating Hepcidin-25 Is Reduced by Endogenous Estrogen in Humans.

Authors:  Mikael Lehtihet; Ylva Bonde; Lena Beckman; Katarina Berinder; Charlotte Hoybye; Mats Rudling; John H Sloan; Robert J Konrad; Bo Angelin
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.